

1 **Title:** Biomarker potential of vitreous microRNA in retinal disease: a meta-analysis

2

3 **Authors:** Diana Joseph<sup>1</sup>, Brian Grover<sup>1</sup>, Michael Telias<sup>1</sup>.

4

5 **Affiliations:** <sup>1</sup>Flaum Eye Institute, University of Rochester Medical Center, 601 Elmwood Ave, Rochester,  
6 NY 14642.

7

8 **Corresponding Author:** Michael Telias, [Michael\\_Telias@urmc.rochester.edu](mailto:Michael_Telias@urmc.rochester.edu)

9

## 10 **Abstract**

11

12 Background: Acquired retinal diseases such as proliferative diabetic retinopathy and age-related macular  
13 degeneration pose significant challenges in diagnosis and prognosis. The vitreous fluid, situated in the  
14 posterior chamber of the eye behind the lens, holds a close relationship with the inner retina. Within this  
15 milieu, retinal cells secrete a diverse array of biomolecules, potentially harboring vital biomarkers. Among  
16 these, short, non-coding micro-RNAs (miRNAs) emerge as promising candidates. Their dynamic regulation  
17 by various gene signaling mechanisms, enhanced resistance to degradation, and secretion via separate  
18 exocytotic pathways make them particularly significant. Alterations in vitreal miRNA profiles may reflect  
19 pathological states and offer insights into disease etiology and progression.

20 Abstract: We conducted a comprehensive meta-analysis of 22 peer-reviewed studies to assess the  
21 potential of vitreous miRNAs as biomarkers for retinal diseases. Our analysis demonstrates the potential  
22 utility of miRNAs as biomarkers in specific retinal pathologies. We show that miR-142, miR-9, and miR-21  
23 emerge as robust biomarker candidates, displaying consistent and significant alterations correlating with  
24 proliferative vitreoretinal diseases. We also address the methodological challenges encountered in

25 characterizing vitreous miRNA content, including the absence of standardized purification, amplification,  
26 and analysis protocols, as well as the scarcity of true control samples. Moreover, we make the case for  
27 the adoption of specific housekeeping genes and data normalization techniques to standardize miRNA  
28 analysis in the vitreous and explore potential methodologies for obtaining vitreous samples from healthy  
29 individuals.


30 **Conclusion:** Vitreous miRNAs hold promise as potential biomarkers for various retinal diseases, with miR-  
31 142, miR-9, and miR-21 emerging as particularly promising candidates. Enhancing methodologies for  
32 vitreous sampling and miRNA analysis presents an opportunity to expand the repertoire and utility of  
33 miRNA biomarkers in retinal disease diagnosis and prognosis.

34

35 **Keywords:** micro-RNA, vitreous humor, retina, liquid biopsy, biomarker, diagnosis, retinal disease

36

37



38

39 **Graphic abstract.** From left to right, the diagram shows the location of the retina and the vitreous humor  
40 within the eye; the microanatomy of the retinal layers showcasing the secretion of exosomes and  
41 biomolecules into the vitreous from its anterior side (inner retinal layers); a magnified illustration of  
42 miRNA secretion process from gene expression in the cell nucleus to exosome -dependent and -

43 independent secretion pathways; and the process of intravitreal biopsy for collection and analysis of  
44 miRNA expression using quantitative PCR methods.

45

46

#### 47 **Background**

48 Retinal diseases can be hereditary, such as a retinitis pigmentosa, a disease affecting the  
49 photoreceptor layer of the retina, while others are acquired. Acquired diseases may be related to  
50 underlying cardiovascular disease (i.e. hypertensive retinopathy, retinal vein occlusion), diabetes mellitus  
51 (i.e. non-proliferative diabetic retinopathy -NPDR-, proliferative diabetic retinopathy -PDR-), or  
52 malignancy (i.e. melanoma, lymphoma). Other acquired retinal conditions are not directly caused by  
53 systemic disease but are more likely to occur in patients with retinal risk factors. For example, patients  
54 with pathological myopia (PM) and lattice degeneration are at greater risk for retinal detachment (RD)  
55 (1). Lack of known genetic causes behind acquired retinal diseases precludes strategies aimed to  
56 preventing their occurrence (e.g.: by preimplantation genetic screening), or to diagnose them before  
57 onset, as it can happen with late onset inherited retinal dystrophies.

58 Moreover, as compared to hereditary retinal diseases, acquired retinal diseases are far more  
59 prevalent in the population, and represent some of the most common causes behind vision loss and  
60 blindness. For example, age-related macular degeneration (AMD) has a prevalence of over 10% in US  
61 adults over the age of 40 and is the leading cause of blindness in elderly persons (2). Diabetic retinopathy  
62 (DR) affects over 40% of the growing population of patients with diabetes mellitus (3). Many of these  
63 diseases also progress over time. For example, both AMD and DR can progress to more severe forms,  
64 characterized by abnormal growth of blood vessels in the retina (4, 5), which further deteriorates vision  
65 in an irreversible way in the absence of treatment. As such, early detection of acquired retinal diseases is  
66 critical to preventing further vision loss.

67           However, early diagnosis of retinal diseases can be challenging. Exam skills, such as  
68 ophthalmoscopy, and imaging tools, like optical coherence tomography, enable visualization of the  
69 affected layers of the retina in most diagnoses. However, not all diagnoses are clear, and sometimes  
70 further investigation is required. For example, intraocular tumors can be mistaken for uveitis,  
71 necessitating a chorio-retinal biopsy to rule out malignancy (6). Not only do biopsies provide a more  
72 definitive diagnostic tool, but they can also further our basic scientific understanding of the molecular  
73 pathology in the sampled tissue. Unfortunately, chorio-retinal biopsies are invasive procedures, and the  
74 indications are limited to identifying infectious organisms affecting the retina, evaluating uveitis, and  
75 excluding malignancy. As a result, for most retinal diseases which do not necessitate a diagnostic biopsy,  
76 our understanding of the molecular pathogenesis is limited. Animal models, such as rodents, rabbits, dogs,  
77 and non-human primates, have undergone retinal biopsies for the study of retinal disease (7-9). However,  
78 the utility of animal models is limited by sample size for larger animals and differences in physiology and  
79 anatomy between smaller animals and humans. Moreover, recapitulating a non-inherited disease in an  
80 animal which does not develop the disease spontaneously, is complicated, time-consuming, and usually  
81 produces partial results, where the gap between humans and model animals remains large.

82           Liquid biopsy of the vitreous humor may provide a less invasive alternative to the chorio-retinal  
83 biopsy. The vitreous humor is a gel-like fluid filling the posterior chamber of the eye between the lens and  
84 the retina, in direct contact with the inner retina. The vitreous is composed of water, hyaluronan,  
85 hyalocytes (i.e. macrophages populating the posterior vitreous cortex), collagen and additional soluble  
86 proteins (10). The vitreous is important for maintaining the round structure of the eye and plays a role in  
87 refraction as light must pass through the vitreous to reach the retina (11). The vitreous humor is accessible  
88 for liquid biopsy (i.e.: vitrectomy) via an incision in the sclera. Analogous to how cerebrospinal fluid is  
89 collected through a lumbar puncture in order to evaluate central nervous system pathology, without the  
90 need to access the brain or spinal cord, vitreous humor can be biopsied to study basic and clinical aspects

91 of retinal pathology (12). For example, in patients with PDR, retinal ischemia induces the release of  
92 vascular endothelial growth factor (VEGF) in the retina, which then leaks into the vitreous body, resulting  
93 in higher levels of vitreal VEGF (10, 13). In vitreoretinal diseases, such as PDR, proliferative  
94 vitreoretinopathy (PVR), and rhegmatogenous retinal detachment (RRD), the inflammatory proteins AAT,  
95 APOA4, ALB, and TF were found to be elevated compared to healthy controls, indicating that these  
96 proteins may contribute to their pathogenesis (14). Similarly, patients with diabetic macular edema, AMD,  
97 idiopathic epiretinal membranes (ERM), and macular telangiectasia type 2 show abnormal expression of  
98 various proteins in the vitreous humor (15). Furthermore, the stability created by interaction between  
99 hyaluronic acid and collagen fibrils within the vitreous also slows clearance, allowing persistence of  
100 molecules associated with disease (10). The variations in vitreous composition reflecting retinal pathology  
101 along with their persistence in the vitreous body suggest that the fluid may hold utility as a biomarker and  
102 diagnostic tool. In the future, vitreous humor may surpass chorio-retinal biopsy and provide insight into  
103 the pathogenesis of various retinal diseases.

104 One type of biomolecule found in vitreous humor is microRNA (miRNA), a class of small non-  
105 coding RNA that regulates gene expression. For example, miRNAs may silence gene transcription under  
106 certain conditions by hybridizing target messenger RNA (mRNA) to prevent protein translation or tag the  
107 mRNA for degradation (16). Extracellularly, miRNAs mediate communication between cells, with effects  
108 ranging from development of mesenchymal stem cells (17), to apoptosis of vascular cells (18). A benefit  
109 of miRNAs as an extracellular entity, in contrast to other forms of RNA or proteins, is its size. Averaging  
110 21-25 nucleotides, miRNAs are small enough to avoid nucleases and resist changes in heat and pH across  
111 different bodily fluids (19). This characteristic has allowed miRNAs to serve as a potential biomarker for  
112 many hematologic and solid cancers (20), temporal lobe epilepsy (21), acute myocardial infarction (22),  
113 and sepsis (23).

114           Of the extracellular miRNAs found in vitreous humor, approximately 10% are secreted through  
115           exosomes (24). Exosomes are extracellular vesicles, typically 40-160 nm, derived from endosomes and  
116           secreted by most cell types, including those of the retina (25). Exosome vesicles contain cell constituents  
117           such as proteins, lipids, RNA, and DNA, and can release their contents into neighboring or distant target  
118           cells (26). Although the exact function of exosomes is unknown, this targeted transfer of contents suggests  
119           that they are involved in intercellular communication. The potential roles of exosomes span widely across  
120           wound healing, immunity, cellular differentiation, and more (25). Exosomes have been isolated in most  
121           bodily fluids, including blood, saliva, urine, and cerebrospinal fluid, and the contents of these exosomes  
122           have been found to be altered by disease (27). For example, serum levels of miR-21 have been significantly  
123           increased in patients with esophageal and hepatocellular carcinoma (28, 29). Similarly, salivary exosome  
124           levels of miR-1246 and miR-4644 are significantly higher in pancreato-biliary tract cancers, and the  
125           combined levels of these miRNAs have potential as a sensitive screening tool for these cancers (30).  
126           Furthermore, exosomal miR-142-5p and miR-223 were found to be significantly upregulated in breast milk  
127           as an early detector of intramammary infection (31). However, while serum, saliva and breast milk are  
128           accessible through safe and relatively simple collection methods, other fluids like cerebrospinal fluid and  
129           vitreous require more invasive techniques and more advanced clinical skills, therefore limiting their  
130           accessibility for research, and almost completely precluding the possibility of collecting control samples  
131           from healthy counterparts.

132           In this meta-analysis, we searched the current literature for peer-reviewed scientific evidence  
133           linking changes in vitreous composition with retinal disease, focusing on miRNA characterization and  
134           quantification. Out of 126 studies that were screened, we found 22 that specifically addressed the  
135           question of miRNAs in vitreous biopsies of retinal disease patients, and reanalyzed the data they provide.  
136           Overall, our meta-analysis shows that vitreal miRNAs do serve as useful biomarkers in certain retinal  
137           diseases such as proliferative diabetic retinopathy, age-related macular degeneration, and proliferative

138 vitreoretinal disease. However, the consistency of data regarding miRNA content in human vitreous is  
139 limited by the fact that no gold standard for miRNA purification and amplification has yet been  
140 established. Additionally, studies lack a source of true control samples as vitreous can only be collected  
141 when a patient is undergoing vitrectomy, and patients only undergo vitrectomy when their eye is in some  
142 state of disease. In recognition of these challenges, we propose using certain housekeeping genes and  
143 data normalization techniques to standardize the analysis of miRNA in the vitreous, and we explore  
144 potential methodologies for obtaining vitreous samples from healthy patients. Finally, we identify miR-  
145 142, miR-9, and miR-21 as the strongest candidates for use as biomarkers of certain reginal diseases.  
146 Specifically, these miRNAs were upregulated in proliferative diabetic retinopathy and proliferative  
147 vitreoretinal disease.

148

## 149 **Main Text**

### 150 **1. Meta-analysis methodology**

151

#### 152 ***Search methods for identifying studies.***


153 Studies were identified via PubMed search with the search terms “exosome vitreous” and  
154 “microRNA vitreous” (**Figure 1**). The scope of articles was limited to studies published after 2012,  
155 considering that there were no studies describing miRNA in vitreous humor prior to 2013 (12). The last  
156 search was performed on January 23, 2024. All studies were reviewed by one reviewer, and selected  
157 studies were confirmed by a second reviewer with subsequent resolution of conflicting ideas.

158

#### 159 ***Eligibility criteria.***

160 All selected studies were peer-reviewed, primary research articles reporting original data. Only  
161 studies that collected vitreous samples from human subjects were included. Selected studies researched

162 diseases that directly affect the retina, including primary retinal pathologies and metastases to the retina,  
163 but excluded anterior segment diseases. With regards to methodology, all selected studies performed  
164 miRNA isolation using a microarray kit from a tested manufacturer, such as Qiagen, Exiquon, or TRIzol,  
165 followed by miRNA quantification with either qPCR, next generation sequencing (NGS), or a microarray  
166 scanner. All studies must have tested significance of differential expression of miRNA, either exosomal or  
167 non-exosomal, against control samples that were also derived from vitreous humor. Studies that had a  
168 sample size less than 2 for any cohort were excluded. Studies that did not show evidence of miRNAs in  
169 the vitreous were excluded as well.  
170



171

172 **Figure 1. Flowchart describing search methodology and exclusion criteria.**

173

174 ***Data synthesis and analysis.***

175 Exosomal and non-exosomal miRNAs that were found to be dysregulated in disease were identified  
176 within the selected studies as well as in any supplementary tables. Gene Ontology (GO) and Kyoto

177 Encyclopedia of Genes and Genomes (KEGG) analysis were conducted on these miRNAs using the DIANA  
178 mirPath v.4 pathway analysis web server, analyzing the most commonly dysregulated miRNAs for disease  
179 categories that had at least five relevant studies (32). When searching for commonly dysregulated  
180 miRNAs, we first studied individual isoforms and then grouped them by mature miRNA family. Statistical  
181 analysis was conducted through the DIANA mirPath v.4 software, using the “classical analysis” option,  
182 which uses one-sided Fisher’s Exact tests to determine significance ( $p < 0.05$ ).

183

## 184 **2. Meta-analysis results**

### 185 ***Vitreous humor sampling and molecular isolation.***

186 The studies assessing the potential of vitreous biopsies as a diagnostic tool included various  
187 diseases but were limited to populations requiring vitrectomies. The studies also varied significantly in  
188 their miRNA extraction and purification techniques due to the lack of a gold standard among the many  
189 commercially available technologies designed to isolate and purify specific types of RNA.

190 The vitreous humor is routinely extracted in humans through an invasive procedure known as a  
191 vitrectomy. Vitrectomies are routinely performed as treatment for RD, macular holes (MH), ERM,  
192 posterior vitreous detachment, and vitreous hemorrhage. Vitrectomies may also be necessitated due to  
193 complications in cataract surgery, such as posterior capsule rupture, which occurs in 0.45-7.9% of cataract  
194 surgeries (33), and in patients with dislocated intraocular lens (34). While vitrectomies must be performed  
195 in the operating room, vitreous humor can also be safely sampled in the clinic prior to intravitreal  
196 injections, which are commonly done for the treatment of diabetic retinopathy, neovascular AMD, and  
197 retinal vein occlusions (35). However, in-office sampling is not routine, and the studies reviewed were  
198 thus limited to subjects who required vitrectomies as treatment. As such, control subjects did not have  
199 non-pathological eyes but rather required a vitrectomy for visual disturbance from conditions such as  
200 idiopathic floaters, MH, ERM. Therefore, control samples were defined as obtained from patients with

201 minimal risk of visual loss progression and blindness, as compared to the studied diseases. The  
202 invasiveness of the vitrectomy limited the sample sizes of all studies.

203

204 After collecting the vitreous humor, all the studies, except those done by Liu et al. and Tuo et al., specified  
205 that the vitrectomy samples were immediately stored at -80 °C prior to experimentation, to prevent RNA  
206 degradation. After the frozen vitreous samples were thawed, miRNAs were isolated using commercially  
207 available purification kits. The volume of vitreous humor collected through vitrectomy, varies from study  
208 to study, and within patients in the same study, but was typically 1-5 ml. Although there are no RNA  
209 isolation kits specifically designed for vitreous humor, studies have compared the efficacy of various kits  
210 for use in small samples of other body fluids such as plasma and urine. For example, TRIzol reagent  
211 (Invitrogen) has lower yield for miRNA with low guanine and cytosine content (36). However, the results  
212 of TRIzol extraction aligns most closely with miRNA documented in the miRBase database compared to  
213 miRNeasy mini kit (Qiagen) (37). Cell count and density of the sample also impact which isolation kit is  
214 preferred. For miRNA extracted from cells in culture, both miRNeasy and TRIzol had greater RNA yields  
215 than miRCURY (Qiagen) at lower cell counts, and miRNeasy outperformed both TRIzol and miRCURY at  
216 both low and high cell densities (38). While a gold standard for miRNA isolation in vitreous humor has yet  
217 to be established, the variability across isolation methods in other biofluids suggests a similar potential  
218 for variability in vitreous humor, which may account for some of the differences across the reviewed  
219 studies. Of the reviewed studies that isolated total miRNA, 13 used miRNeasy, 4 used TRIzol and 1 used  
220 miRCURY.

221 To extract exosomal miRNAs, an additional step is required to isolate the exosomes first.  
222 Exosomes can either be isolated from vitreous humor via a combination of ultracentrifugation and  
223 filtration, known as differential centrifugation, or via centrifugation followed by an exosome isolation kit  
224 such as miRCURY Exosome Kit (Qiagen) or RiboTM Exosome Isolation Reagent (RiboBio). Differential

225 centrifugation is considered the gold standard for exosome isolation, and isolation kits may lead to the  
226 inclusion of non-exosomal particles (39). However, ultracentrifugation requires costly equipment that  
227 isolation kits avoid. Of the reviewed studies which isolated miRNA from exosomes, two used differential  
228 centrifugation, while two employed an isolation kit.

229

### 230 *miRNA changes in total vitreous biopsy across diseases.*

231 The reviewed studies varied in their level of specificity when reporting dysregulated miRNA  
232 expression. For example, some reported the mature miRNA family that was dysregulated (e.g.: miR-125)  
233 while others also included a suffix (i.e.: -3p, -5p), specifying an isoform within the miRNA family. miRNA  
234 isoforms were considered separate molecules and are denoted by different letters (e.g.: miR-125a vs miR-  
235 125b). When searching for the most commonly dysregulated miRNAs across all of the studies, we included  
236 both the overall miRNA families, as well as individual isoforms.

237 With regards to the miRNA families, miR-16 was most commonly dysregulated, with 9 occurrences  
238 in 7 different studies (**Table 1**). miR-16 was upregulated in all instances except in the case of PM, where it  
239 was downregulated. This may reflect the pathogenesis of PM compared to the other diseases. While PM  
240 is characterized by chorio-retinal atrophy, all the other pathologies involved proliferative or cancerous  
241 processes. In addition, the study on PM included controls that had RRD. The inflammatory and immune  
242 reaction to RRD could cause miRNA dysregulation, making miR-16 relatively downregulated in subjects  
243 with PM. Other commonly dysregulated miRNA families include miR-125b, miR-139, and miR-423, as  
244 described in **Table 1**.

245 Comparing specific isoforms, miR-423-5p was most frequently dysregulated with 6 different  
246 studies finding it to be upregulated, as seen in **Table 1**. The next most frequently dysregulated miRNA was  
247 miR-320b, which does not have -3p or -5p isoforms according to the miRBase database. miR-320b was

248 consistently upregulated in 5 different studies investigating PDR, PM, and primary vitreoretinal lymphoma  
 249 (PVRL) (40-44).  
 250

miRNA	Study	Disease	Isoform	Up- or Down-regulation
<b>miR-16</b>	Usui-Ouchi 2016	PVRD	-	↑
	Ragusa 2015	UM	-	↑
	Smit-McBride 2020	Type 1 DM with PDR	-	↑
	Minezaki 2020	PVRL	miR-16-1-3p	↑
			miR-16-2-3p	↑
			miR-16-5p	↑
	Kot 2022	PDR	miR-16-5p	↑
You 2023	PM	miR-16-5p	↓	
Guo 2021	PDR	miR-16-5p	↑	
<b>miR-125b</b>	You 2023	PM	miR-125b-1-3p	↑
			miR-125b-2-3p	↑
			miR-125b-5p	↑
	Minezaki 2020	PVRL	miR-125b-1-3p	↑
			miR-125b-5p	↑
Smit-McBride 2020	Type 2 DM with NPDR	miR-125b-1-star	↑	

	Kot 2022	PDR	miR-125b-5p	↓
	Guo 2021	PDR	miR-125b-5p	↑
<b>miR-139</b>	You 2023	PM	miR-139-3p	↓
			miR-139-5p	↓
	Guo 2021	PDR	miR-139-3p	↑
	Minezaki 2020	PVRL	miR-139-3p	↑
	Smit-McBride 2020	Type II DM with PDR and NPDR	miR-139-3p	↑
	Usui-Ouchi 2016	PVRD	miR-139-5p	↓
	Toro 2020	Retinal detachment with PVR	miR-139-5p	↑
	Ragusa 2015	UM	miR-139-5p	↓
<b>miR-423</b>	You 2023	PM	miR-423-3p	↑
			miR-423-5p	↑
	Guo 2021	PDR	miR-423-3p	↑
			miR-423-5p	↑
	Hirota 2014	PDR	miR-423-5p	↑
	Usui-Ouchi 2016	PVRD	miR-423-5p	↑
Minezaki 2020	PVRL	miR-423-5p	↑	
Smit-McBride 2020	Type I and II DM with PDR	miR-423-5p	↑	

251 **Table 1. Correlation between changes in human vitreous miRNA and retinal diseases.** The table shows  
 252 the most commonly dysregulated miRNA across all diseases included in the present meta-analysis. PVRD:  
 253 proliferative vitreoretinal disease, UM: uveal melanoma, DM: diabetes mellitus, PDR: proliferative

254 diabetic retinopathy, PVRL: primary vitreoretinal lymphoma, PM: pathologic myopia, NPDR: non-  
255 proliferative diabetic retinopathy, PVR: proliferative vitreoretinopathy

256

### 257 ***miRNA in diabetic retinopathy***

258 DR can be categorized as NPDR, the less severe form, or PDR, the more advanced form, which is  
259 characterized by breakdown of the barrier between the retina and its surrounding blood vessels (3). Of  
260 the ten articles in our analysis that studied DR, only one studied NPDR while the remaining nine focused  
261 on PDR. Pramanik et al. compared miRNA in Type 2 DM patients with and without NPDR and found that  
262 NPDR patients had significantly decreased levels of miR-126 and miR-132 in both the vitreous humor and  
263 plasma (45). Furthermore, ROC curve analysis showed that the fold change of miR-126 and miR-132 in the  
264 vitreous humor had greater sensitivity and specificity as a predictor of NPDR compared to the fold change  
265 in plasma, indicating that the vitreous miRNAs have better diagnostic utility for retinal disease than serum  
266 miRNA (45). Of the seven studies in our analysis that researched PDR, the two studies by Liu et al. and Kot  
267 et al. specifically isolated exosomal miRNA and are detailed further in section 3.3.1 below, while the  
268 remaining seven articles studied miRNA found in the total vitreous humor.

269 Given that abnormal blood vessel growth is part of the pathogenesis of PDR, several of the studies  
270 correlated miRNA that were dysregulated in PDR with angiogenesis. For example, Hirota et al. identified  
271 five miRNAs (miR-15a, miR-320a, miR-320b, miR-93, and miR-29a) that were significantly elevated in the  
272 vitreous humor in patients with PDR and thought to be involved in angiogenesis (40). For example, miR-  
273 15a has been shown to inhibit angiogenesis in response to ischemia by reducing the activity of fibroblast  
274 growth factor 2 and VEGF, indicating that miR-15a may have protective effects in PDR (46). Guo et al.  
275 identified three miRNAs (miR-24-3p, miR-197-3p, and miR-3184-3p) that were not only significantly  
276 upregulated in PDR but also correlated with increased levels of VEGF and transforming growth factor-  $\beta$   
277 (TGF $\beta$ ) in the vitreous humor (43). In contrast, Gomaa et al. showed that miR-200b was elevated in PDR

278 but it did not correlate with vitreous levels of VEGF (47). Yang et al. identified seven miRNA that were  
279 elevated in PDR, and KEGG analysis showed that the target genes of these miRNA were most enriched in  
280 the Th17 cell differentiation pathway (48). Notably, interleukin-17, which is produced by Th17 cells, has  
281 been shown to promote retinal neovascularization through multiple mechanisms (49-51).

282 The high glucose conditions caused by diabetes also contribute to the pathogenesis of PDR,  
283 Shanbagh et al. specifically studied how these conditions affected miRNA and target protein levels (52).  
284 They found that miR-182-5p was upregulated in patients with PDR, and under high glucose conditions,  
285 RPE cells had higher expression of miR-182-5p. The study also showed that the downstream effects of  
286 elevated miR-182-5p expression included downregulation of FoxO1 and upregulation of Akt and HK2,  
287 which are known to be involved in metabolic regulation (53, 54). These findings show that miR-182-5p  
288 may have a role in the pathogenesis of PDR through its effects on glucose metabolism.

289 Smit-McBride et al. differentiated between Type 1 and Type 2 DM when studying miRNA in the  
290 vitreous of patients with PDR. They identified four miRNA families (let-7, miR-320b, miR-4488, and miR-  
291 762) that were upregulated in patients with PDR with both types of DM as compared to controls with MH  
292 or macular pucker (41). Although these miRNAs have not been studied in the retina, let-7 targets  
293 regulatory cytokines that promote angiogenesis and has been linked to increased risk of Type 2 DM (55,  
294 56). Interestingly, miR-320b has been shown to be anti-angiogenic via its regulation of neuropilin 1 and  
295 insulin-like growth factor 1, indicating that the increased levels of miR-320b in PDR may be a  
296 compensatory mechanism attempting to attenuate disease progression (57, 58).

297 Because the retinal blood vessels that form in PDR are abnormal, they are at high risk of bleeding  
298 into the neighboring vitreous humor. Mammadzada et al. were the only researchers to specifically look at  
299 PDR that was complicated by recurrent vitreous hemorrhage. They found that miR-20a and miR-93 were  
300 significantly elevated in patients who later developed recurrent vitreous hemorrhage, and both miRNA  
301 are known to be involved in angiogenesis. Increased levels of miR-20a have been shown to downregulate

302 VEGF protein expression, but miR-20a is also known to be downregulated by hypoxic conditions (59). Of  
 303 note, miR-20a was also found to be elevated in the study by Friedrich et al. (60). miR-93, which was also  
 304 found to be upregulated in the study by Hirota et al., has been shown to modulate angiogenesis through  
 305 multiple mechanisms, including by directly binding the VEGF-A gene and by promoting endothelial cell  
 306 proliferation and migration by targeting cyclin-dependent kinase inhibitor 1A (59, 61, 62)

307 Given that VEGF is considered a primary driver of neovascularization in PDR, anti-VEGF  
 308 medications have become a standard treatment and have been shown to improve visual acuity in PDR  
 309 (63). Friedrich et al. not only identified miRNA that were elevated in PDR but also found that miR-23b-3p  
 310 levels were subsequently lowered after anti-VEGF treatment (60). Further investigation into the targets  
 311 of miR-23b-3p is needed. Overall, there were three families of mature miRNAs that were found to have  
 312 four isoforms dysregulated in at least three of the nine studies, as shown in **Table 2**.

313

miRNA	Study	Isoform	Up- or Down- Regulation	Enriched Signaling Pathways
<b>miR-142</b>	Kot 2022	miR-142-3p	↑	p53***
		miR-142-5p	↑	VEGF*
	Friedrich 2020	miR-142-3p	↑	PI3K-Akt*
	Guo 2021	miR-142-5p	↑	
<b>miR-423</b>	Guo 2021	miR-423-3p	↑	p53**
		miR-423-5p	↑	HIF-1*
	Hirota 2014	miR-423-5p	↑	MAPK**
	Smit-McBride 2020	miR-423-5p	↑	PI3K-Akt***
<b>miR-9</b>	Kot 2022	miR-9-3p	↓	p53**

		miR-9-5p	↓	MAPK*
	Liu 2022	miR-9-3p	↑	
	Guo 2021	miR-9-5p	↑	

314 **Table 2. Correlation between changes in human vitreous miRNA expression and PDR.** The table shows  
 315 the miRNA families with 24 instances of dysregulation, across studies, in PDR; and the molecular signaling  
 316 pathways they affect related to diabetes, with or without retinopathy. \*p<0.01, \*\*p<0.001, \*\*\*p<0.0001.

317  
 318 KEGG analysis through the DIANA-miRPath database showed that all three miRNA families (miR-  
 319 142, miR-423, and miR-9) were connected to pathways in diabetes and diabetic retinopathy. For example,  
 320 all three are involved in the p53 signaling pathway, which is known to be connected to Type 2 Diabetes  
 321 Mellitus (DM), because p53 inhibition preserves pancreatic insulin secretion (64). Furthermore, p53  
 322 protein and mRNA have been shown to be upregulated in retinal pericytes and human retinal vascular  
 323 endothelial cells under high glucose conditions, showing a possible role in the early development of  
 324 diabetic retinopathy (65, 66). One limitation of KEGG analysis is that although it can determine whether a  
 325 miRNA targets a certain pathway, it does not specify whether the pathway is enhanced or suppressed by  
 326 the miRNA. In this case, if the miRNA were shown to upregulate the p53 signaling pathway, that would  
 327 provide further evidence in their role in the pathogenesis of PDR.

328 The VEGF signaling pathway is considered a primary driver for the vascular proliferation that  
 329 characterizes PDR (67, 68). Only miR-142 directly enriched the VEGF signaling pathway, but both miR-142  
 330 and miR-423 enriched related pathways. For example, miR-423 targeted the hypoxia-inducible factor  
 331 (HIF)-1 signaling pathway, which is known to increase retinal VEGF in diabetic retinopathy. As its name  
 332 suggests, HIF-1 is induced by small vessel hypoxia in the retina created by diabetes and then mediates  
 333 retinal neovascularization through the release of VEGF and erythropoietin (69-72). Therefore, miRNA that  
 334 activate HIF-1 signaling would theoretically worsen diabetic retinopathy while miRNA that suppress it


335 could be protective. Further research is required to determine how miR-423 levels correlate with HIF-1.  
336 Similarly, miR-142 and miR-423 targeted the phosphatidylinositol 3-kinase (PI3K)-Akt signaling pathway.  
337 Activation of PI3K-Akt can increase VEGF expression by upregulating the HIF-1 signaling pathway or by  
338 phosphorylating endothelial nitric oxide synthase, which is a necessary step in VEGF-induced angiogenesis  
339 (73, 74). miRNA activation of the PI3K-Akt pathway would increase neovascularization in PDR. Both miR-  
340 423 and miR-9 enriched the MAPK signaling pathway, which is activated by the VEGF signaling pathway,  
341 and is known to cause retinal inflammation and fibrosis in PDR (75). In fact, MAPK inhibition in retinal  
342 mouse models decreased inflammatory and angiogenic markers such as nitric oxide and cyclooxygenase-  
343 2 (76, 77). Upregulation of MAPK by miRNA would thus contribute to the development of PDR.

344         When evaluating the use of the miRNAs as biomarkers for PDR, both their specificity and  
345 consistency must be considered. Although miR-423 is consistently found to be upregulated in PDR, it is  
346 also commonly upregulated in other disorders such as PM and PVRL (**Table 1**). This lack of specificity for  
347 PDR indicates that miR-423 may be a more general marker of retinal cell dysfunction. On the other hand,  
348 although miR-9 was not found to be dysregulated as frequently as miR-423, its results were inconsistent.  
349 Forms of the miR-9 family were downregulated in the study by Kot et al. but upregulated in the studies  
350 by Liu et al. and Guo et al (43, 78, 79). These differences may be due to variations in subject choice and  
351 study design. In the study by Kot et al., the PDR subjects had disease that was complicated by tractional  
352 RD, meaning the PDR was severe enough to produce a fibrous proliferative membrane that created  
353 enough traction to cause detachment of the neurosensory layer of the retina (80). In the other two  
354 studies, the PDR was not complicated by tractional RD, and the RD and its treatment may have impacted  
355 the miRNA composition. Also, Kot et al. used qPCR to quantify assayed miRNA while Liu et al. and Guo et  
356 al. used NGS. Although Guo et al. verified the results of their NGS with qPCR, the initial choice of miRNA  
357 quantification technique may have led to varied results. Until these discrepancies can be resolved, the  
358 utility of miR-9 as a biomarker is limited. miR-142, however, was consistently upregulated across studies

359 and was more specifically upregulated in the setting of PDR. This, combined with its direct and indirect  
360 influence on the VEGF pathway, makes miR-142 an important potential biomarker for PDR.

361 The three most commonly dysregulated miRNA families, with at least four instances of  
362 dysregulation in at least three different studies, listed in **Table 2** as well as the 16 next most commonly  
363 dysregulated miRNA families, with at least three instances of dysregulation (Supp. Table 1) were selected  
364 for pooled GO and KEGG analysis (see **Figure 2 & 3**). KEGG analysis resulted in 141 related pathways.  
365 Notably, ubiquitin-mediated proteolysis, protein processing in the endoplasmic reticulum, cell cycle, and  
366 p53 signaling pathways, are all related to Type 2 DM according to the KEGG pathway database. GO analysis  
367 revealed 1174 targeted categories, with 547 results in the biological component domain, 163 in molecular  
368 function, and 245 in the cellular component.


369



370

371 **Figure 2. KEGG analysis of human vitreous miRNAs in PDR.** Top 10 most enriched KEGG pathways for the  
372 19 most commonly dysregulated (23 instances of dysregulation) miRNA species in proliferative diabetic  
373 retinopathy, including 41 isoforms. The miRNA number indicates the number of inputted miRNAs that are  
374 involved in each pathway and the gene number indicates the number of experimentally validated target  
375 coding-genes of the inputted miRNAs that are involved in each pathway. The top 10 pathways had p-  
376 values <1E-11 (one-sided Fisher's exact test, p<0.05).

377



378

379 **Figure 3. GO-terms analysis of human vitreous miRNAs in PDR.** Top 10 most enriched GO terms for the  
380 19 most commonly dysregulated (23 instances of dysregulation) miRNA species in proliferative diabetic  
381 retinopathy, including 41 isoforms. The top 10 terms had p-values <1E-49 (one-sided Fisher's exact test,  
382 p<0.05).

383

384 ***miRNA in proliferative vitreoretinal disease***

385 Proliferative vitreoretinal disease (PVRD) is a category encompassing diseases with a proliferative  
386 element to their pathogenesis, including PVR following trauma or RD and PDR. In our analysis, the study  
387 by Usui-Ouchi et al. encompassed both PDR and PVR, and Toro et al. focused on PVR due to RD (81, 82).  
388 We identified 25 of the most commonly dysregulated miRNAs (with at least 3 instances of dysregulation)  
389 among these two studies as well as the 9 looking at PDR alone (Supp. Table 2). As with PDR alone, the  
390 miR-9 and mir-423 families were two of the most commonly dysregulated, with miR-9-5p upregulated in  
391 PVR and miR-423-5p upregulated in general PVRD. GO and KEGG analysis of these 50 miRNAs showed  
392 almost complete overlap with the results from PDR alone. However, one notable difference was that the  
393 p53 signaling pathway was not in the top 10 most enriched pathways for PVRD although it was for PDR  
394 alone. As noted above, the p53 signaling pathway is known to be related to the pathogenesis of Type 2  
395 DM, so it is reasonable that this pathway would be less targeted in PVR, a non-diabetic process. Instead,  
396 the neurotrophin-signaling pathway was in the top KEGG pathways for PVRD, although it was not among  
397 the most enriched pathways in PDR.

398 Usui-Ouchi et al. argue that the shared proliferative process in PDR and PVR would lead to similar  
399 alterations in miRNAs. In particular, they highlight miR-21 as increasing in relation to retinal fibrosis in  
400 PVRD. In fact, miR-21-5p is found to be upregulated in the studies by Guo et al. and Kot et al looking at  
401 PDR. However, miR-21-3p is downregulated in the PVR study by Toro et al. This discrepancy highlights the  
402 need for specification of miRNA isoforms across studies. Although both isoforms have the same mature  
403 miRNA, the differences in their precursors could affect how they correlate to pathology. In the past,  
404 studies may have been limited by the available microarrays, but moving forward, researchers should aim  
405 to specify the miRNA isoforms.

406 Another miRNA that may be involved in the pathogenesis of PVR is miR-148a-3p, which was found  
407 to elevated in patients with retinal detachments (83). Although the study subjects did not yet have

408 progression to PVR, Takayama et al. showed that transfection of miR-148a-3p into human retinal pigment  
 409 epithelium (RPE) cells promoted epithelial–mesenchymal transition, a process that characterizes PVR (83,  
 410 84).

411

412 ***miRNA in primary vitreoretinal lymphoma.***

413 Two studies, by Tuo et al. and Minezaki et al., identified miRNA that are dysregulated in primary  
 414 vitreoretinal lymphoma (PVRL) in comparison to uveitis (44, 85). Because PVRL can be mistaken for uveitis,  
 415 leading to delay in proper treatment, there is need for a distinguishing biomarker. The miRNAs found to  
 416 be dysregulated in PVRL compared to uveitis in both studies can be found in **Table 3**, but only the results  
 417 from Minezaki et al. are statistically significant.

418

miRNA	Study	Tail	Up- or Downregulation
<b>miR-200c</b>	Tuo 2013	-	↓
	Minezaki 2020	miR-200c-5p	↑*
<b>miR-484</b>	Tuo 2013	-	↑
	Minezaki 2020	-	↑*
<b>miR-197</b>	Tuo 2013	-	↑
	Minezaki 2020	miR-197-3p	↑*
	Minezaki 2020	miR-195-5p	↑*
<b>miR-132</b>	Tuo 2013	-	↑
	Minezaki 2020	miR-132-3p	↑*

419 **Table 3. Dysregulated human vitreous miRNA in PVRL, as compared to uveitis.** Only the results reported  
 420 by Minezaki et al. were statistically significant (t-test, \*p<0.05).

421

422 Tuo et al. focused on miR-155, which they not only found to be significantly decreased in  
423 lymphoma patients but was also inversely correlated with IL-10, which is known to be secreted heavily in  
424 B-cell PVRL. However, miR-155 was not found to be dysregulated by Minezaki et al. One reason for the  
425 variation in significance and miRNAs identified between the two studies may be their sample sizes. Tuo et  
426 al. had only 3 PVRL and 3 uveitis samples for the microarray while Minezaki et al. had 6 each. However,  
427 Tuo et al. confirmed the results of the microarray with individual assays and qPCR from a larger sample of  
428 17 PVRL and 12 uveitis subjects. Minezaki et al. used a microarray scanner to quantify the miRNAs and did  
429 not validate the results with qPCR. Also, the choice of microarray may have impacted the  
430 comprehensiveness of study results. The microarray used by Tuo et al. (the microRNA-CURY panel from  
431 Exiquon) tested for only 168 miRNAs while the 3D-Gene miRNA Oligo Chip used by Minezaki et al. tested  
432 for 2565 miRNAs. Further studies comparing miRNA in PVRL and uveitis should employ large-scale  
433 microarrays as done by Minezaki et al. but with the secondary validation schema outlined by Tuo et al.

434

#### 435 ***miRNA in pathologic myopia.***

436 PM is defined by an axial length of at least 26.5 mm or a refractive error of at least -6.00 diopters.  
437 Patients with PM are at risk for progressive vision loss due to chorioretinal atrophy as well as RD. Two  
438 studies in our review analyzed changes to non-exosomal and exosomal miRNA in the vitreous humor of  
439 subjects with PM. Ando et al. found that let-7c was upregulated in PM while miR-200a was downregulated  
440 (86). These results are confirmed by You et al., who found let-7c-5p to be upregulated while miR-200a-3p  
441 was downregulated in PM (42). Ando et al. argued that let-7c may be secreted by Müller glial cells  
442 migrating to the inner limiting membrane of the retina in highly myopic eyes. KEGG pathway analysis of  
443 miR-200a completed by Ando et al. showed that the let-7c was related to the PI3K/Akt signaling pathway,  
444 which may increase axial length by stimulating proteins such as insulin-like growth factor-1 and matrix  
445 metalloproteinase-2, which are known to be related to PM. You et al. identified 143-3p and miR-145-5p

446 as key miRNA through weighted gene co-expression network analysis. Like Ando et al., You et al. showed  
447 that miR-143-3p and miR-145-5p may relate to axial length by potentially increasing the expression of  
448 insulin-like growth factor. One reason that Ando et al. may not have detected dysregulation of miR-143-  
449 3p and miR-145-5p is that these miRNAs were detected within exosomes. As discussed later in this review,  
450 exosomal miRNA can be more stable than non-exosomal miRNA and thus serve as more reliable  
451 biomarkers.

452

### 453 ***miRNAs in age-related macular degeneration.***

454 The pathogenesis of AMD involves several layers of the retina: the photoreceptor layer becomes  
455 less dense, there is hyperpigmentation and atrophy of the RPE, and lipid-rich materials known as drusen  
456 are deposited between the RPE and Bruch's membrane (4). In the more advanced form, wet or  
457 neovascular AMD, there is neovascularization of the macula (4). Despite its prevalence, to the best of our  
458 knowledge, there is only one study looking at miRNA in the vitreous humor in neovascular AMD. Menard  
459 et al. noted upregulation of miR-146a and downregulation of miR-106b and miR-152 in patients with  
460 neovascular AMD compared to controls (87). The study goes on to argue that the ratio of miR-146a to  
461 miR-106b collected from both vitreous humor and plasma can be used as a biomarker for neovascular  
462 AMD, based on receiver operating characteristic (ROC) analysis. According to Menard et al., miR-146a may  
463 have a protective mechanism in the retina by downregulating inflammatory cytokines. Meanwhile,  
464 decreased miR-106b levels may worsen neovascular AMD by influencing VEGF-A and IL-8 regulation. This  
465 was the only study to consider the ratio of two miRNA as a biomarker, but while this approach is unique,  
466 it comes with limitations. miR-146a and miR-106b are proposed to have separate mechanisms for  
467 advancing neovascular AMD, so if one of these mechanisms progresses at a slower-than-expected rate,  
468 then the ratio will be skewed. This study's sample size was 26, but a larger follow-up study could be used  
469 to verify the findings and establish a diagnostic range for the ratio.

470

471 ***miRNAs in intraocular tuberculosis.***

472           Intraocular tuberculosis (IOTB) can occur as a result of systemic tuberculosis or via direct infection  
473 of the eye. Although it most commonly presents as posterior uveitis, it can also affect the retina, usually  
474 through spread from the choroid, presenting as focal tubercles, subretinal abscesses, or diffuse retinitis  
475 (88). These findings are thought to be caused by an inflammatory response to bacteria-laden  
476 macrophages depositing their contents in the ocular blood supply (89). To our knowledge, only one study  
477 has analyzed vitreous-derived miRNA. Chadalawada et al. used NGS followed by validation with qPCR to  
478 identify 3 miRNA (miR-150-5p, miR-26b-5p, and miR-21-5p) that were upregulated in IOTB compared to  
479 controls with MH (90). Furthermore, the study used ROC analysis to identify a combination of miR-21-5p  
480 and miR-26b-5p as having the highest potential as a biomarker. Interestingly, the study noted that miR-  
481 21-5p may have immune regulated anti-inflammatory effects in IOTB, which contrasts with miR-21's pro-  
482 fibrotic role in the pathogenesis in PVRD as discussed above. Given that miR-21 isoforms have been found  
483 to be dysregulated in 5 of our studies, it is important that further research is done to investigate its  
484 mechanism of action in retinal diseases.

485

486 ***Exosomes in disease.***

487           Exosomal miRNA may be even better markers of retinal disease than non-exosomal RNA.  
488 Exosomes are secreted into the vitreous humor by surrounding cells, such as retinal cells, providing  
489 miRNAs that reflect the state of the diseased parent cell (91). Exosomal miRNAs are protected from  
490 degradation by RNAses and show increased stability. In addition, exosomes have specific proteins and  
491 markers, and this uniqueness allows for more targeted analysis of low abundance exosomal cargo (91).  
492 Within the vitreous humor, exosomes are particularly good choice for finding biomarkers due to their  
493 abundance. Over 60% of proteins isolated from vitreous humor are consistent with exosomes, according

494 to gene ontology analysis of vitreous humor proteins (92). Moreover, almost 50% of the vitreous humor  
 495 proteins thought to be within the exosomes are associated with retinal disease, furthering the argument  
 496 that exosomal cargo can be used as indicators of retinal health (92). In fact, studies have already shown  
 497 that vitreous humor exosomes may affect immunomodulation and angiogenesis (93, 94). Here, we review  
 498 how exosomal miRNA vary with disease and evaluate their potential as biomarkers.

499

500 ***Exosomal miRNA.***

501 Thus far, there are only four studies that have identified dysregulated miRNA in exosomes from  
 502 the vitreous humor. The most notable miRNAs from each study are outlined in **Table 4**. Both Ragusa et al.  
 503 and You et al. used differential ultracentrifugation, the gold standard, to isolate exosomes from vitreous  
 504 humor, while Kot et al. and Liu et al. used a combination of centrifugation and an exosome isolation kit.

505

Study	Disease	Control	Sample Size	miRNA	Up- or Down-regulation
Ragusa 2015	UM	Healthy cornea donors	6 UM	miR-21	↑
			6 control	miR-34a	↑
				miR-146a	↑
				miR-618	↑
Liu 2022	PDR	MH	10 PDR	miR-9-3p	↑
			15 control	miR-23b-3p	↑
				miR-1285-3p	↑
				miR-4685-3p	↑
Kot 2022	PDR with	MH	10 PDR with	miR-21-5p	↑
	TRD		TRD	miR-125a-5p	↓

				10 control	miR-125b-5p miR-204-5p miR-412-3p let-7g-5p	↓ ↓ ↓ ↑
You 2023	PM-L and PM-H		RRD, MH, or ERM	5 PM-L 8 PM-H 12 control	miR-26a-5p miR-204-3p miR-204-5p miR126-3p miR-143-3p miR-145-5p miR-151a-3p	↓ <sup>+</sup> ↓ <sup>+</sup> ↓ <sup>+</sup> ↓ <sup>+</sup> ↓ ↓ ↓ <sup>+</sup>

506 **Table 4. Dysregulated miRNA found within human vitreal exosomes.** Summary of miRNA within vitreous  
507 humor exosomes that have thus far been studied and identified as dysregulated in comparison to the  
508 listed controls ( $p < 0.05$ ). UM: uveal melanoma, MH: macular hole, PDR: proliferative diabetic retinopathy,  
509 TRD: tractional retinal detachment, PM-L: low grade pathologic myopia, PM-H: high grade pathologic  
510 myopia, RRD: rhegmatogenous retinal detachment, ERM: epiretinal membrane. The table includes select  
511 miRNA that were emphasized in the primary study, see original publication for full list of dysregulated  
512 miRNAs. Up- or down- regulation noted with ‘+’ is comparing miRNA in PM-H to miRNA in PM-L, rather  
513 than to the control group.

514  
515 Ragusa et al. was the first to look at exosomal miRNA in the vitreous humor, and they did so in  
516 the context of uveal melanoma (UM). The study looked at non-exosomal miRNA as well and found that  
517 there was a 90% overlap between non-exosomal and exosomal miRNA in UM, indicating that the non-

518 exosomal miRNA may have altered by exosomes. Considering how exosomal miRNA reflect the parent  
519 cells, the study argues that miR-21 and miR-146a, which were found to be upregulated, come from  
520 neighboring neoplastic melanocytes. They show this by demonstrating that miR-146a was also  
521 upregulated in formalin-fixed paraffin-embedded UM specimens. A limitation of this study, however, is  
522 the choice of subjects. The vitreous humor was taken from enucleated eyes for the UM group and cornea  
523 donors for the control group. The miRNA composition, both exosomal and non-exosomal, could be altered  
524 by the removal of the eyes.

525 While shared miRNA dysregulation between Liu et al. and Kot et al. was discussed in the section  
526 on miRNA in PDR, the study by Liu et al. has further importance regarding exosomes. Liu et al.  
527 demonstrated that retinal Müller glia cells secrete exosomes containing miR-9-3p, and these miRNAs  
528 promote angiogenesis via overexpression of sphingosine 1-phosphate receptor 1 (S1P1). Again, this shows  
529 a direct connection between retinal cells and miRNA within vitreous humor exosomes. However, although  
530 this connection was demonstrated *in vivo*, it utilized a mouse model, which has limited transferability to  
531 humans. Further study in humans and animal models will be required to determine the exact role of  
532 exosomal miR-9-3p in PDR.

533

## 534 **Conclusions**

535 The objective of this meta-analysis was to assess the potential usefulness of miRNAs identified in  
536 vitreous humor as biomarkers and diagnostic aids for a range of acquired retinal diseases. Among 126  
537 initial studies surveyed, only 22 presented pertinent data concerning the composition of miRNAs in human  
538 vitreous biopsies within the context of retinal disease, covering conditions such as PDR, PVRD, PVRL, PM,  
539 AMD, and intraocular TB. Our revision of published data reveals promising prospects for utilizing miRNA  
540 molecular analysis in human vitreous biopsies as a feasible means of identifying and quantifying clinically  
541 relevant biomarkers. Moreover, the exploration of vitreous miRNAs holds potential for offering valuable

542 insights into the molecular mechanisms underlying various retinal diseases. Nonetheless, significant  
543 challenges lie ahead, including the variability in extraction and purification methodologies, the  
544 establishment of robust criteria for selecting control samples, the identification of suitable and universally  
545 applicable housekeeping genes, and the validation of predictive capabilities for each proposed marker.  
546 Addressing these challenges will be crucial for advancing the clinical translation of miRNA-based  
547 diagnostics in retinal disease.

548           Our analysis revealed that variability across miRNA isolation and purification kits generally did not  
549 affect the consistency of results. However, differences in amplification methods may have contributed to  
550 contradictory findings. For instance, in three studies using three different kits (Kot et al. used miRCury,  
551 Friedrich et al. used TRizol, and Guo et al. used miRNeasy), all three found miR-142 to be upregulated in  
552 PDR (43, 60, 78). Nevertheless, while Kot et al. used qPCR for miRNA quantification, Liu et al. and Guo et  
553 al. initially used NGS, potentially accounting for their disparate findings regarding miR-9 dysregulation in  
554 PDR. Although no gold standard exists for miRNA quantification in vitreous biopsies, studies on limited  
555 volumes of serum and plasma recommend initial quantification with NGS followed by validation with qPCR  
556 to maximize miRNA detection sensitivity and reliability (95). While varying results among isolation kits and  
557 amplification techniques have been investigated in other human biofluids, the emerging nature of this  
558 field means there is yet no gold standard for miRNA extraction and quantification from vitreous humor,  
559 affecting the quality of results.

560           Due to the invasiveness of a vitrectomy, all subjects in the studies, including those considered  
561 ‘controls’, had a clinical indication for a vitrectomy, creating a lack of a *true control*. Most of the control  
562 cases required vitrectomies for idiopathic MH, ERM, or floaters, all of which are conditions caused by age-  
563 related changes to the vitreous. However, the pathophysiology of MH remains unknown, while the  
564 pathophysiology of ERM includes cell proliferation and fibrosis, which may also be occurring in the studied  
565 diseases, obscuring data (96, 97). For example, Russo et al. found that miR-19b, miR-24, and miR-142-3p

566 were significantly upregulated in patients with idiopathic MH or ERM compared to idiopathic floaters (98).  
567 The miR-142 family was also found to be commonly upregulated in PDR when compared to controls with  
568 MH, indicating that there may be overlap in the pathogenesis of these idiopathic conditions and PDR.

569 For vitreous-derived miRNAs to be proven as biomarkers and indicators of pathogenesis, studies  
570 must use controls that do not have any underlying pathologies, but this is made challenging due to the  
571 invasiveness of a vitrectomy. Currently, most miRNA purification kits work reliably in fluid samples of  
572 ~100-200  $\mu$ l, while the human vitreous volume is estimated at ~4.0 ml (99). A current alternative to  
573 vitrectomies would be to obtaining vitreous samples during intraocular injections. However, this restricts  
574 the collection of samples exclusively to those receiving the treatment in question. Future vitreous biopsy  
575 techniques with minimal invasiveness could involve the use of thinner and smaller catheters and needles,  
576 to extract a very small volume (<100  $\mu$ l) from awake patients, eliminating the use of vitrectomy- or  
577 injection-dependent biopsies.

578 Variations in miRNA expression across studies could also be caused by different strategies for  
579 normalizing miRNA quantification data. Our studies reported 3 different normalization techniques – 7  
580 used a housekeeping gene, 5 used an exogenous control, and 9 normalized against a weighted or  
581 unweighted average or median expression of the miRNA quantities. The housekeeping gene used by all 7  
582 studies was the small nuclear-RNA U6, a widely used reference gene. A review of miRNA-analysis using  
583 qPCR in cancer studies showed that 84% of studies used U6 as the reference gene (100). However, the  
584 expression of U6 was shown to vary with experimental conditions and disease, suggesting potential  
585 limitations in its use as a universal housekeeping gene (101, 102). Other studies have shown that the ideal  
586 housekeeping gene varies based on disease state and the biological fluid being studied, and mathematical  
587 models such as geNorm, NormFinder, and BestKeeper should be used to identify a housekeeping gene  
588 that is optimal for vitreous humor (100, 103). This holds particular significance as a gold standard

589 housekeeping gene would alleviate the challenge of small sample sizes in these studies, facilitating more  
590 straightforward pooling of data.

591 One possible solution to the variability in the expression of housekeeping genes is the use of an  
592 exogenous control. For example, cel-miR-39 -added to the vitreous samples- was used by several studies  
593 reviewed here. Exogenous controls studies in the serum of cancer patients indeed showed less inter-  
594 sample variability than endogenous controls (104). One drawback of exogenous controls, however, is that  
595 because they are added in just prior to RNA isolation, they do not control for experimental variability that  
596 occurs prior to this step (105). Other analysis strategies involve normalizing the expression of the target  
597 gene to the rest of the genes within a microarray, either by averaging them, finding the median, or  
598 identifying a few miRNAs that resemble the mean. While these strategies are mostly appropriate for high-  
599 throughput studies with several hundreds of miRNAs, they have been shown to produce more accurate  
600 results than reference genes in tumor samples (105, 106). One study, by Ando et al., used a housekeeping  
601 gene, as well as the median expression level, to normalize the quantification of the target genes(86). Until  
602 a standard housekeeping gene is identified and confirmed, normalization using a combination of  
603 housekeeping genes and general average values may be the best approach.

604 Another barrier to building on the reviewed studies to identify clinically applicable biomarkers is  
605 their validation, especially given their limited sample sizes. Two of the revised studies attempted to  
606 strengthen their findings by concurrently studying miRNA in the serum of their subjects. However, the  
607 two studies had opposing approaches. For example, Minezaki et al. found that miR-6513-3p, miR-138-2f-  
608 3p and miR-4445-3p were elevated in vitreous and serum of PVRL patients as compared to uveitis patients,  
609 but they did not compare the relative expression of miRNAs in vitreous vs serum for each patient (44). In  
610 contrast, Hirota et al. reported an increase in the expression of miR-23a, miR-320a, and miR-320b in the  
611 vitreous of PDR patients, as compared to the serum of the same PDR patients and as compared to vitreous  
612 samples from controls (40). This suggests that upregulation of these miRNAs in PDR is an intraocular-

613 specific process, rather than a systemic one, providing new insights into PDR pathogenesis. The strategy  
614 used by Minezaki et al., looking for a positive correlation between vitreous and serum miRNA levels, may  
615 be more useful for validating biomarkers involved in systemic diseases. If successful, this approach can  
616 lead to serum biopsies replacing vitreous altogether, while still providing data that is clinically relevant for  
617 ocular and retinal diseases. The approach by Hirota et al. could be more useful for changes localized to  
618 the eye. Beyond biomarker validation, results that are tissue-dependent can carry with them potential  
619 mechanistic insights. Overall, there is currently little data to guide the interpretation of miRNA levels in  
620 vitreous vs serum, and how these comparisons should affect the potential of miRNA as diagnostic  
621 biomarkers.

622         Among the three most commonly dysregulated miRNAs in PDR, miR-142 emerged as consistently  
623 upregulated and specific to PDR, presenting itself as a potential biomarker. However, while KEGG analysis  
624 indicated pathway enrichments related to diabetes and diabetic retinopathy, further elucidation of miR-  
625 142's role in the underlying pathology of PDR is necessary. On the other hand, miR-9 garnered substantial  
626 evidence supporting its involvement in the pathogenesis of PDR, thereby enhancing its potential as a  
627 biomarker. Notably, Liu et al. demonstrated elevated levels of miR-9 in exosomes derived from retinal  
628 Muller cells, with miR-9 facilitating angiogenesis through the targeting of the S1P1/AKT/VEGFR2 pathway.  
629 Moreover, miR-9's angiogenic effects via S1P1 targeting in tumor endothelial cells underscore its  
630 significance (107). Additionally, KEGG analysis highlighted miR-9's involvement in the p53 and MAPK  
631 pathways, both implicated in PDR pathogenesis (65, 66, 75). These findings collectively underscore miR-  
632 9's potential as a crucial pathological indicator of PDR, notwithstanding its downregulation in the study  
633 by Kot et al., which could be attributed to population differences or methodological disparities in miRNA  
634 quantification.

635         Turning attention to PVRD, miR-21 emerged as dysregulated in four studies, with elevated levels  
636 correlating with PVRD pathogenesis. For instance, Usui-Ouchi et al. demonstrated TGF- $\beta$ -induced

637 upregulation of miR-21 expression in RPE cells, promoting RPE cell proliferation (81). Given the prominent  
638 role of TGF- $\beta$  in inflammation and cell proliferation, and its targeting in PDR treatment, the study suggests  
639 a potential pathogenic role for miR-21 in diabetic retinopathy (108-110). Furthermore, miR-21-dependent  
640 promotion of fibrosis in various contexts, suggests its contribution to the retinal fibrosis observed in PVRD  
641 (111-113). Against the reported downregulation of miR-21 in the study by Toro et al., its consistent  
642 upregulation in three other studies suggests potential isoform-specific differences contributing to this  
643 discrepancy. Further confirmatory studies validating miR-21-5p upregulation in vitreous humor in PVRD  
644 would be valuable, given the established role of miR-21 in retinal and systemic fibrosis, cementing its  
645 emerging status as a pathological marker in PVRD.

646 In conclusion, it is important to acknowledge the limitations of the current analysis, notably the  
647 small sample sizes in most studies, and the variability in methodologies for miRNA purification,  
648 amplification, and quantification across studies. Additionally, the heterogeneous selection of control  
649 groups, ranging from healthy individuals to those with minimal risk of disease progression, poses a  
650 challenge to this emerging field. Nonetheless, our findings suggest that specific miRNA, including miR-142,  
651 miR-9, and miR-21, hold promise as diagnostic tools for their respective diseases. Further research is  
652 needed to validate and expand these findings and advance the clinical integration of miRNA as biomarkers  
653 for retinal diseases.

654

## 655 **References**

656

- 657 1. Morano MJ, Khan MA, Zhang Q, Halfpenny CP, Wisner DM, Sharpe J, et al. Incidence and Risk  
658 Factors for Retinal Detachment and Retinal Tear after Cataract Surgery: IRIS(R) Registry (Intelligent  
659 Research in Sight) Analysis. *Ophthalmol Sci.* 2023;3(4):100314.

- 660 2. Rein DB, Wittenborn JS, Burke-Conte Z, Gulia R, Robalik T, Ehrlich JR, et al. Prevalence of Age-  
661 Related Macular Degeneration in the US in 2019. *JAMA Ophthalmol.* 2022;140(12):1202-8.
- 662 3. Kempen JH, O'Colmain BJ, Leske MC, Haffner SM, Klein R, Moss SE, et al. The prevalence of  
663 diabetic retinopathy among adults in the United States. *Arch Ophthalmol.* 2004;122(4):552-63.
- 664 4. Vyawahare H, Shinde P. Age-Related Macular Degeneration: Epidemiology, Pathophysiology,  
665 Diagnosis, and Treatment. *Cureus.* 2022;14(9):e29583.
- 666 5. Wang W, Lo ACY. Diabetic Retinopathy: Pathophysiology and Treatments. *Int J Mol Sci.*  
667 2018;19(6).
- 668 6. Ragusa M, Barbagallo C, Statello L, Caltabiano R, Russo A, Puzzo L, et al. miRNA profiling in vitreous  
669 humor, vitreal exosomes and serum from uveal melanoma patients: Pathological and diagnostic  
670 implications. *Cancer Biol Ther.* 2015;16(9):1387-96.
- 671 7. Constable IJ, Horne R, Slatter DH, Chester GH, Cooper RL. Regeneration of retinal limiting  
672 membranes after chorioretinal biopsy in dogs. *Invest Ophthalmol Vis Sci.* 1981;20(2):246-51.
- 673 8. Bird AC, Farber DB, Kreiger AE, Straatsma BR, Bok D. The potential usefulness to research of retina  
674 obtained by biopsy. *Invest Ophthalmol Vis Sci.* 1988;29(1):2-11.
- 675 9. Cloutier F, Lawrence M, Goody R, Lamoureux S, Al-Mahmood S, Colin S, et al. Antiangiogenic  
676 activity of aganirsen in nonhuman primate and rodent models of retinal neovascular disease after topical  
677 administration. *Invest Ophthalmol Vis Sci.* 2012;53(3):1195-203.
- 678 10. Sebag J. *Vitreous : in Health and Disease.* New York, NY: Springer New York : Imprint: Springer,;  
679 2014.
- 680 11. Zong Y, Gao QY, Hui YN. Vitreous function and intervention of it with vitrectomy and other  
681 modalities. *Int J Ophthalmol.* 2022;15(6):857-67.
- 682 12. Ragusa M, Caltabiano R, Russo A, Puzzo L, Avitabile T, Longo A, et al. MicroRNAs in vitreous humor  
683 from patients with ocular diseases. *Mol Vis.* 2013;19:430-40.

- 684 13. Iyer SSR, Lagrew MK, Tillit SM, Roohipourmoallai R, Korntner S. The Vitreous Ecosystem in Diabetic  
685 Retinopathy: Insight into the Patho-Mechanisms of Disease. *Int J Mol Sci.* 2021;22(13).
- 686 14. Shitama T, Hayashi H, Noge S, Uchio E, Oshima K, Haniu H, et al. Proteome Profiling of Vitreoretinal  
687 Diseases by Cluster Analysis. *Proteomics Clin Appl.* 2008;2(9):1265-80.
- 688 15. Monteiro JP, Santos FM, Rocha AS, Castro-de-Sousa JP, Queiroz JA, Passarinha LA, et al. Vitreous  
689 humor in the pathologic scope: insights from proteomic approaches. *Proteomics Clin Appl.* 2015;9(1-  
690 2):187-202.
- 691 16. O'Brien J, Hayder H, Zayed Y, Peng C. Overview of MicroRNA Biogenesis, Mechanisms of Actions,  
692 and Circulation. *Front Endocrinol (Lausanne).* 2018;9:402.
- 693 17. Collino F, Deregibus MC, Bruno S, Sterpone L, Aghemo G, Viltono L, et al. Microvesicles derived  
694 from adult human bone marrow and tissue specific mesenchymal stem cells shuttle selected pattern of  
695 miRNAs. *PLoS One.* 2010;5(7):e11803.
- 696 18. Zernecke A, Bidzhekov K, Noels H, Shagdarsuren E, Gan L, Denecke B, et al. Delivery of microRNA-  
697 126 by apoptotic bodies induces CXCL12-dependent vascular protection. *Sci Signal.* 2009;2(100):ra81.
- 698 19. Turchinovich A, Samatov TR, Tonevitsky AG, Burwinkel B. Circulating miRNAs: cell-cell  
699 communication function? *Front Genet.* 2013;4:119.
- 700 20. Bayraktar R, Pichler M, Kanlikilicer P, Ivan C, Bayraktar E, Kahraman N, et al. MicroRNA 603 acts  
701 as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation  
702 factor 2 kinase. *Oncotarget.* 2017;8(7):11641-58.
- 703 21. Raoof R, Jimenez-Mateos EM, Bauer S, Tackenberg B, Rosenow F, Lang J, et al. Cerebrospinal fluid  
704 microRNAs are potential biomarkers of temporal lobe epilepsy and status epilepticus. *Sci Rep.*  
705 2017;7(1):3328.

- 706 22. Corsten MF, Dennert R, Jochems S, Kuznetsova T, Devaux Y, Hofstra L, et al. Circulating MicroRNA-  
707 208b and MicroRNA-499 reflect myocardial damage in cardiovascular disease. *Circ Cardiovasc Genet.*  
708 2010;3(6):499-506.
- 709 23. Sun B, Luan C, Guo L, Zhang B, Liu Y. Low expression of microRNA-328 can predict sepsis and  
710 alleviate sepsis-induced cardiac dysfunction and inflammatory response. *Braz J Med Biol Res.*  
711 2020;53(8):e9501.
- 712 24. Condrat CE, Thompson DC, Barbu MG, Bugnar OL, Boboc A, Cretoiu D, et al. miRNAs as Biomarkers  
713 in Disease: Latest Findings Regarding Their Role in Diagnosis and Prognosis. *Cells.* 2020;9(2).
- 714 25. Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. *Science.*  
715 2020;367(6478).
- 716 26. Rahmati S, Shojaei F, Shojaeian A, Rezakhani L, Dehkordi MB. An overview of current knowledge  
717 in biological functions and potential theragnostic applications of exosomes. *Chem Phys Lipids.*  
718 2020;226:104836.
- 719 27. Zhang Y, Liu Y, Liu H, Tang WH. Exosomes: biogenesis, biologic function and clinical potential. *Cell*  
720 *Biosci.* 2019;9:19.
- 721 28. Tanaka Y, Kamohara H, Kinoshita K, Kurashige J, Ishimoto T, Iwatsuki M, et al. Clinical impact of  
722 serum exosomal microRNA-21 as a clinical biomarker in human esophageal squamous cell carcinoma.  
723 *Cancer.* 2013;119(6):1159-67.
- 724 29. Wang H, Hou L, Li A, Duan Y, Gao H, Song X. Expression of serum exosomal microRNA-21 in human  
725 hepatocellular carcinoma. *Biomed Res Int.* 2014;2014:864894.
- 726 30. Machida T, Tomofuji T, Maruyama T, Yoneda T, Ekuni D, Azuma T, et al. miR-1246 and miR-4644  
727 in salivary exosome as potential biomarkers for pancreatobiliary tract cancer. *Oncol Rep.*  
728 2016;36(4):2375-81.

- 729 31. Sun J, Aswath K, Schroeder SG, Lippolis JD, Reinhardt TA, Sonstegard TS. MicroRNA expression  
730 profiles of bovine milk exosomes in response to Staphylococcus aureus infection. BMC Genomics.  
731 2015;16:806.
- 732 32. Vlachos IS, Zagganas K, Paraskevopoulou MD, Georgakilas G, Karagkouni D, Vergoulis T, et al.  
733 DIANA-miRPath v3.0: deciphering microRNA function with experimental support. Nucleic Acids Res.  
734 2015;43(W1):W460-6.
- 735 33. Babu N, Kohli P. Commentary: Advances in anterior vitrectomy. Indian J Ophthalmol.  
736 2023;71(2):647-8.
- 737 34. Mitra RA, Connor TB, Han DP, Koenig SB, Mieler WF, Pulido JS. Removal of dislocated intraocular  
738 lenses using pars plana vitrectomy with placement of an open-loop, flexible anterior chamber lens.  
739 Ophthalmology. 1998;105(6):1011-4.
- 740 35. Pfahler SM, Brandford AN, Glaser BM. A prospective study of in-office diagnostic vitreous  
741 sampling in patients with vitreoretinal pathology. Retina. 2009;29(7):1032-5.
- 742 36. Kim YK, Yeo J, Kim B, Ha M, Kim VN. Short structured RNAs with low GC content are selectively  
743 lost during extraction from a small number of cells. Mol Cell. 2012;46(6):893-5.
- 744 37. Gautam A, Kumar R, Dimitrov G, Hoke A, Hammamieh R, Jett M. Identification of extracellular  
745 miRNA in archived serum samples by next-generation sequencing from RNA extracted using multiple  
746 methods. Mol Biol Rep. 2016;43(10):1165-78.
- 747 38. El-Khoury V, Pierson S, Kaoma T, Bernardin F, Berchem G. Assessing cellular and circulating miRNA  
748 recovery: the impact of the RNA isolation method and the quantity of input material. Sci Rep.  
749 2016;6:19529.
- 750 39. Tang YT, Huang YY, Zheng L, Qin SH, Xu XP, An TX, et al. Comparison of isolation methods of  
751 exosomes and exosomal RNA from cell culture medium and serum. Int J Mol Med. 2017;40(3):834-44.

- 752 40. Hirota K, Keino H, Inoue M, Ishida H, Hirakata A. Comparisons of microRNA expression profiles in  
753 vitreous humor between eyes with macular hole and eyes with proliferative diabetic retinopathy. *Graefes*  
754 *Arch Clin Exp Ophthalmol*. 2015;253(3):335-42.
- 755 41. Smit-McBride Z, Nguyen AT, Yu AK, Modjtahedi SP, Hunter AA, Rashid S, et al. Unique molecular  
756 signatures of microRNAs in ocular fluids and plasma in diabetic retinopathy. *PLoS One*.  
757 2020;15(7):e0235541.
- 758 42. You J, Wu Q, Xu G, Gu C, Allen E, Zhu T, et al. Exosomal MicroRNA Profiling in Vitreous Humor  
759 Derived From Pathological Myopia Patients. *Invest Ophthalmol Vis Sci*. 2023;64(1):9.
- 760 43. Guo J, Zhou P, Pan M, Liu Z, An G, Han J, et al. Relationship between elevated microRNAs and  
761 growth factors levels in the vitreous of patients with proliferative diabetic retinopathy. *J Diabetes*  
762 *Complications*. 2021;35(11):108021.
- 763 44. Minezaki T, Usui Y, Asakage M, Takanashi M, Shimizu H, Nezu N, et al. High-Throughput MicroRNA  
764 Profiling of Vitreoretinal Lymphoma: Vitreous and Serum MicroRNA Profiles Distinct from Uveitis. *J Clin*  
765 *Med*. 2020;9(6).
- 766 45. Pramanik S, Saha C, Chowdhury S, Bose C, Bhattacharyya NP, Mondal LK. Decreased Levels of miR-  
767 126 and miR-132 in Plasma and Vitreous Humor of Non-Proliferative Diabetic Retinopathy Among Subjects  
768 with Type-2 Diabetes Mellitus. *Diabetes Metab Syndr Obes*. 2022;15:345-58.
- 769 46. Yin KJ, Olsen K, Hamblin M, Zhang J, Schwendeman SP, Chen YE. Vascular endothelial cell-specific  
770 microRNA-15a inhibits angiogenesis in hindlimb ischemia. *J Biol Chem*. 2012;287(32):27055-64.
- 771 47. Gomaa AR, Elsayed ET, Moftah RF. MicroRNA-200b Expression in the Vitreous Humor of Patients  
772 with Proliferative Diabetic Retinopathy. *Ophthalmic Res*. 2017;58(3):168-75.
- 773 48. Yang Y, Yue W, Wang N, Wang Z, Li B, Zeng J, et al. Altered Expressions of Transfer RNA-Derived  
774 Small RNAs and microRNAs in the Vitreous Humor of Proliferative Diabetic Retinopathy. *Front Endocrinol*  
775 *(Lausanne)*. 2022;13:913370.

- 776 49. Li Y, Zhou Y. Interleukin-17: The Role for Pathological Angiogenesis in Ocular Neovascular  
777 Diseases. *Tohoku J Exp Med.* 2019;247(2):87-98.
- 778 50. Sui A, Chen X, Yao Y, Yao Y, Shen X, Zhu Y, et al. The IL-23/IL-17 axis promotes the formation of  
779 retinal neovascularization by activating the NLRP3 inflammasome in macrophages in an experimental  
780 retinopathy mouse model. *Immunology.* 2021;164(4):803-16.
- 781 51. Taguchi M, Someya H, Inada M, Nishio Y, Takayama K, Harimoto K, et al. Retinal changes in mice  
782 spontaneously developing diabetes by Th17-cell deviation. *Exp Eye Res.* 2020;198:108155.
- 783 52. Shanbagh S, Gadde SG, Shetty R, Heymans S, Abilash VG, Chaurasia SS, et al. Hyperglycemia-  
784 induced miR182-5p drives glycolytic and angiogenic response in Proliferative Diabetic Retinopathy and  
785 RPE cells via depleting FoxO1. *Exp Eye Res.* 2024;238:109713.
- 786 53. Das F, Ghosh-Choudhury N, Dey N, Bera A, Mariappan MM, Kasinath BS, et al. High glucose forces  
787 a positive feedback loop connecting Akt kinase and FoxO1 transcription factor to activate mTORC1 kinase  
788 for mesangial cell hypertrophy and matrix protein expression. *J Biol Chem.* 2014;289(47):32703-16.
- 789 54. Huang X, Liu G, Guo J, Su Z. The PI3K/AKT pathway in obesity and type 2 diabetes. *Int J Biol Sci.*  
790 2018;14(11):1483-96.
- 791 55. Zhang J, Zhang L, Fan R, Guo N, Xiong C, Wang L, et al. The polymorphism in the let-7 targeted  
792 region of the Lin28 gene is associated with increased risk of type 2 diabetes mellitus. *Mol Cell Endocrinol.*  
793 2013;375(1-2):53-7.
- 794 56. Jiang LQ, Franck N, Egan B, Sjogren RJ, Katayama M, Duque-Guimaraes D, et al. Autocrine role of  
795 interleukin-13 on skeletal muscle glucose metabolism in type 2 diabetic patients involves microRNA let-7.  
796 *Am J Physiol Endocrinol Metab.* 2013;305(11):E1359-66.
- 797 57. Wang XH, Qian RZ, Zhang W, Chen SF, Jin HM, Hu RM. MicroRNA-320 expression in myocardial  
798 microvascular endothelial cells and its relationship with insulin-like growth factor-1 in type 2 diabetic rats.  
799 *Clin Exp Pharmacol Physiol.* 2009;36(2):181-8.

- 800 58. Wu YY, Chen YL, Jao YC, Hsieh IS, Chang KC, Hong TM. miR-320 regulates tumor angiogenesis  
801 driven by vascular endothelial cells in oral cancer by silencing neuropilin 1. *Angiogenesis*. 2014;17(1):247-  
802 60.
- 803 59. Hua Z, Lv Q, Ye W, Wong CK, Cai G, Gu D, et al. MiRNA-directed regulation of VEGF and other  
804 angiogenic factors under hypoxia. *PLoS One*. 2006;1(1):e116.
- 805 60. Friedrich J, Steel DHW, Schlingemann RO, Koss MJ, Hammes HP, Krenning G, et al. microRNA  
806 Expression Profile in the Vitreous of Proliferative Diabetic Retinopathy Patients and Differences from  
807 Patients Treated with Anti-VEGF Therapy. *Transl Vis Sci Technol*. 2020;9(6):16.
- 808 61. Long J, Wang Y, Wang W, Chang BH, Danesh FR. Identification of microRNA-93 as a novel regulator  
809 of vascular endothelial growth factor in hyperglycemic conditions. *J Biol Chem*. 2010;285(30):23457-65.
- 810 62. Shu X, Mao Y, Li Z, Wang W, Chang Y, Liu S, et al. MicroRNA-93 regulates angiogenesis in peripheral  
811 arterial disease by targeting CDKN1A. *Mol Med Rep*. 2019;19(6):5195-202.
- 812 63. Zhao Y, Singh RP. The role of anti-vascular endothelial growth factor (anti-VEGF) in the  
813 management of proliferative diabetic retinopathy. *Drugs Context*. 2018;7:212532.
- 814 64. Hoshino A, Ariyoshi M, Okawa Y, Kaimoto S, Uchihashi M, Fukai K, et al. Inhibition of p53 preserves  
815 Parkin-mediated mitophagy and pancreatic beta-cell function in diabetes. *Proc Natl Acad Sci U S A*.  
816 2014;111(8):3116-21.
- 817 65. Gurel Z, Zaro BW, Pratt MR, Sheibani N. Identification of O-GlcNAc modification targets in mouse  
818 retinal pericytes: implication of p53 in pathogenesis of diabetic retinopathy. *PLoS One*. 2014;9(5):e95561.
- 819 66. Ao H, Liu B, Li H, Lu L. Egr1 mediates retinal vascular dysfunction in diabetes mellitus via promoting  
820 p53 transcription. *J Cell Mol Med*. 2019;23(5):3345-56.
- 821 67. Hampton BM, Schwartz SG, Brantley MA, Jr., Flynn HW, Jr. Update on genetics and diabetic  
822 retinopathy. *Clin Ophthalmol*. 2015;9:2175-93.

- 823 68. Gupta N, Mansoor S, Sharma A, Sapkal A, Sheth J, Falatoonzadeh P, et al. Diabetic retinopathy and  
824 VEGF. *Open Ophthalmol J.* 2013;7:4-10.
- 825 69. Lazzara F, Trotta MC, Platania CBM, D'Amico M, Petrillo F, Galdiero M, et al. Stabilization of HIF-  
826 1alpha in Human Retinal Endothelial Cells Modulates Expression of miRNAs and Proangiogenic Growth  
827 Factors. *Front Pharmacol.* 2020;11:1063.
- 828 70. Min J, Zeng T, Roux M, Lazar D, Chen L, Tudzarova S. The Role of HIF1alpha-PFKFB3 Pathway in  
829 Diabetic Retinopathy. *J Clin Endocrinol Metab.* 2021;106(9):2505-19.
- 830 71. Arjamaa O, Nikinmaa M. Oxygen-dependent diseases in the retina: role of hypoxia-inducible  
831 factors. *Exp Eye Res.* 2006;83(3):473-83.
- 832 72. Cheng L, Yu H, Yan N, Lai K, Xiang M. Hypoxia-Inducible Factor-1alpha Target Genes Contribute to  
833 Retinal Neuroprotection. *Front Cell Neurosci.* 2017;11:20.
- 834 73. Karar J, Maity A. PI3K/AKT/mTOR Pathway in Angiogenesis. *Front Mol Neurosci.* 2011;4:51.
- 835 74. Fukumura D, Gohongi T, Kadambi A, Izumi Y, Ang J, Yun CO, et al. Predominant role of endothelial  
836 nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular  
837 permeability. *Proc Natl Acad Sci U S A.* 2001;98(5):2604-9.
- 838 75. Saika S, Yamanaka O, Ikeda K, Kim-Mitsuyama S, Flanders KC, Yoo J, et al. Inhibition of p38MAP  
839 kinase suppresses fibrotic reaction of retinal pigment epithelial cells. *Lab Invest.* 2005;85(7):838-50.
- 840 76. Du Y, Tang J, Li G, Berti-Mattera L, Lee CA, Bartkowski D, et al. Effects of p38 MAPK inhibition on  
841 early stages of diabetic retinopathy and sensory nerve function. *Invest Ophthalmol Vis Sci.*  
842 2010;51(4):2158-64.
- 843 77. Guo Y, Guo C, Ha W, Ding Z. Carnosine improves diabetic retinopathy via the MAPK/ERK pathway.  
844 *Exp Ther Med.* 2019;17(4):2641-7.
- 845 78. Kot A, Kaczmarek R. Exosomal miRNA Profiling in Vitreous Humor in Proliferative Diabetic  
846 Retinopathy. *Cells.* 2022;12(1).

- 847 79. Liu Y, Yang Q, Fu H, Wang J, Yuan S, Li X, et al. Muller glia-derived exosomal miR-9-3p promotes  
848 angiogenesis by restricting sphingosine-1-phosphate receptor S1P(1) in diabetic retinopathy. *Mol Ther*  
849 *Nucleic Acids*. 2022;27:491-504.
- 850 80. Mishra C, Tripathy K. *Retinal Traction Detachment*. StatPearls. Treasure Island (FL)2023.
- 851 81. Usui-Ouchi A, Ouchi Y, Kiyokawa M, Sakuma T, Ito R, Ebihara N. Upregulation of Mir-21 Levels in  
852 the Vitreous Humor Is Associated with Development of Proliferative Vitreoretinal Disease. *PLoS One*.  
853 2016;11(6):e0158043.
- 854 82. Toro MD, Reibaldi M, Avitabile T, Bucolo C, Salomone S, Rejdak R, et al. MicroRNAs in the Vitreous  
855 Humor of Patients with Retinal Detachment and a Different Grading of Proliferative Vitreoretinopathy: A  
856 Pilot Study. *Transl Vis Sci Technol*. 2020;9(6):23.
- 857 83. Takayama K, Kaneko H, Hwang SJ, Ye F, Higuchi A, Tsunekawa T, et al. Increased Ocular Levels of  
858 MicroRNA-148a in Cases of Retinal Detachment Promote Epithelial-Mesenchymal Transition. *Invest*  
859 *Ophthalmol Vis Sci*. 2016;57(6):2699-705.
- 860 84. Hoerster R, Muether PS, Vierkotten S, Hermann MM, Kirchhof B, Fauser S. Upregulation of TGF-  
861 ss1 in experimental proliferative vitreoretinopathy is accompanied by epithelial to mesenchymal  
862 transition. *Graefes Arch Clin Exp Ophthalmol*. 2014;252(1):11-6.
- 863 85. Tuo J, Shen D, Yang HH, Chan CC. Distinct microRNA-155 expression in the vitreous of patients  
864 with primary vitreoretinal lymphoma and uveitis. *Am J Ophthalmol*. 2014;157(3):728-34.
- 865 86. Ando Y, Keino H, Inoue M, Hirota K, Takahashi H, Sano K, et al. Circulating Vitreous microRNA as  
866 Possible Biomarker in High Myopic Eyes with Macular Hole. *Int J Mol Sci*. 2022;23(7).
- 867 87. Menard C, Rezende FA, Miloudi K, Wilson A, Tetreault N, Hardy P, et al. MicroRNA signatures in  
868 vitreous humour and plasma of patients with exudative AMD. *Oncotarget*. 2016;7(15):19171-84.
- 869 88. Neuhouser AJ, Sallam A. *Ocular Tuberculosis*. StatPearls. Treasure Island (FL)2023.

- 870 89. Gupta V, Gupta A, Rao NA. Intraocular tuberculosis--an update. *Surv Ophthalmol.* 2007;52(6):561-  
871 87.
- 872 90. Chadalawada S, Rathinam SR, Lalitha P, Kannan NB, Devarajan B. Detection of microRNAs  
873 expression signatures in vitreous humor of intraocular tuberculosis. *Mol Biol Rep.* 2023;50(12):10061-72.
- 874 91. Nik Mohamed Kamal NNSB, Shahidan WNS. Non-Exosomal and Exosomal Circulatory MicroRNAs:  
875 Which Are More Valid as Biomarkers? *Frontiers in Pharmacology.* 2020;10.
- 876 92. Zhao Y, Weber SR, Lease J, Russo M, Siedlecki CA, Xu LC, et al. Liquid Biopsy of Vitreous Reveals  
877 an Abundant Vesicle Population Consistent With the Size and Morphology of Exosomes. *Transl Vis Sci*  
878 *Technol.* 2018;7(3):6.
- 879 93. Wooff Y, Cioanca AV, Chu-Tan JA, Aggio-Bruce R, Schumann U, Natoli R. Small-Medium  
880 Extracellular Vesicles and Their miRNA Cargo in Retinal Health and Degeneration: Mediators of  
881 Homeostasis, and Vehicles for Targeted Gene Therapy. *Frontiers in Cellular Neuroscience.* 2020;14.
- 882 94. Klingeborn M, Dismuke WM, Bowes Rickman C, Stamer WD. Roles of exosomes in the normal and  
883 diseased eye. *Prog Retin Eye Res.* 2017;59:158-77.
- 884 95. Hong LZ, Zhou L, Zou R, Khoo CM, Chew ALS, Chin CL, et al. Systematic evaluation of multiple qPCR  
885 platforms, NanoString and miRNA-Seq for microRNA biomarker discovery in human biofluids. *Sci Rep.*  
886 2021;11(1):4435.
- 887 96. Majumdar S, Tripathy K. Macular Hole. *StatPearls.* Treasure Island (FL)2023.
- 888 97. Kanukollu VM, Agarwal P. Epiretinal Membrane. *StatPearls.* Treasure Island (FL)2023.
- 889 98. Russo A, Ragusa M, Barbagallo C, Longo A, Avitabile T, Uva MG, et al. miRNAs in the vitreous  
890 humor of patients affected by idiopathic epiretinal membrane and macular hole. *PLoS One.*  
891 2017;12(3):e0174297.
- 892 99. Azhdam AM, Goldberg RA, Ugradar S. In Vivo Measurement of the Human Vitreous Chamber  
893 Volume Using Computed Tomography Imaging of 100 Eyes. *Transl Vis Sci Technol.* 2020;9(1):2.

- 894 100. Veryaskina YA, Titov SE, Zhimulev IF. Reference Genes for qPCR-Based miRNA Expression Profiling  
895 in 14 Human Tissues. *Med Princ Pract.* 2022;31(4):322-32.
- 896 101. Xiang M, Zeng Y, Yang R, Xu H, Chen Z, Zhong J, et al. U6 is not a suitable endogenous control for  
897 the quantification of circulating microRNAs. *Biochem Biophys Res Commun.* 2014;454(1):210-4.
- 898 102. Madadi S, Schwarzenbach H, Lorenzen J, Soleimani M. MicroRNA expression studies: challenge of  
899 selecting reliable reference controls for data normalization. *Cell Mol Life Sci.* 2019;76(18):3497-514.
- 900 103. Donati S, Ciuffi S, Brandi ML. Human Circulating miRNAs Real-time qRT-PCR-based Analysis: An  
901 Overview of Endogenous Reference Genes Used for Data Normalization. *Int J Mol Sci.* 2019;20(18).
- 902 104. Vigneron N, Meryet-Figuere M, Guttin A, Issartel JP, Lambert B, Briand M, et al. Towards a new  
903 standardized method for circulating miRNAs profiling in clinical studies: Interest of the exogenous  
904 normalization to improve miRNA signature accuracy. *Mol Oncol.* 2016;10(7):981-92.
- 905 105. Mestdagh P, Van Vlierberghe P, De Weer A, Muth D, Westermann F, Speleman F, et al. A novel  
906 and universal method for microRNA RT-qPCR data normalization. *Genome Biol.* 2009;10(6):R64.
- 907 106. Ban E, Song EJ. Considerations and Suggestions for the Reliable Analysis of miRNA in Plasma Using  
908 qRT-PCR. *Genes (Basel).* 2022;13(2).
- 909 107. Yao X, Xie L, Zeng Y. MiR-9 Promotes Angiogenesis via Targeting on Sphingosine-1- Phosphate  
910 Receptor 1. *Front Cell Dev Biol.* 2020;8:755.
- 911 108. Hirase K, Ikeda T, Sotozono C, Nishida K, Sawa H, Kinoshita S. Transforming growth factor beta2  
912 in the vitreous in proliferative diabetic retinopathy. *Arch Ophthalmol.* 1998;116(6):738-41.
- 913 109. Chen HY, Ho YJ, Chou HC, Liao EC, Tsai YT, Wei YS, et al. The Role of Transforming Growth Factor-  
914 Beta in Retinal Ganglion Cells with Hyperglycemia and Oxidative Stress. *Int J Mol Sci.* 2020;21(18).
- 915 110. Bonfiglio V, Platania CBM, Lazzara F, Conti F, Pizzo C, Reibaldi M, et al. TGF-beta Serum Levels in  
916 Diabetic Retinopathy Patients and the Role of Anti-VEGF Therapy. *Int J Mol Sci.* 2020;21(24).

917 111. Thum T, Gross C, Fiedler J, Fischer T, Kissler S, Bussen M, et al. MicroRNA-21 contributes to  
918 myocardial disease by stimulating MAP kinase signalling in fibroblasts. *Nature*. 2008;456(7224):980-4.

919 112. Liu G, Friggeri A, Yang Y, Milosevic J, Ding Q, Thannickal VJ, et al. miR-21 mediates fibrogenic  
920 activation of pulmonary fibroblasts and lung fibrosis. *J Exp Med*. 2010;207(8):1589-97.

921 113. Zhu H, Luo H, Li Y, Zhou Y, Jiang Y, Chai J, et al. MicroRNA-21 in scleroderma fibrosis and its  
922 function in TGF-beta-regulated fibrosis-related genes expression. *J Clin Immunol*. 2013;33(6):1100-9.

923

924

925

## 926 **List of Abbreviations**

927 AMD – Age-related Macular Degeneration

928 ERM – Epiretinal Membrane

929 DR – Diabetic Retinopathy

930 MH – Macular Hole

931 miRNA - microRNA

932 NPDR – Non-Proliferative Diabetic Retinopathy

933 PDR - Proliferative Diabetic Retinopathy

934 PM – Pathological Myopia

935 PVR – Proliferative Vitreoretinopathy

936 PVRD - Proliferative vitreoretinal disease

937 PVRL – Primary Vitreoretinal Lymphoma

938 RD – Retinal Detachment

939 RRD – Rhegmatogenous Retinal Detachment

940

941 **Declarations**

942 **Ethics approval and consent to participate:** Not applicable

943 **Consent for publication:** Not applicable

944 **Availability of data and materials:** All data generated or analyzed during this study are included in this  
945 published article, and its supplementary information files.

946 **Competing interests:** The authors declare that they have no competing interests.

947 **Funding:** This study was supported by Research to Prevent Blindness (RPB) Career Development Award to  
948 MT and RPB Unrestricted Gift to the Flaum Eye Institute, University of Rochester Medical Center.

949 **Authors contributions:** DJ designed and conducted the research; collected and interpreted the data;  
950 wrote the manuscript. BG assisted in manuscript writing and editing. MT conceptualized the study and  
951 designed the research; assisted in data interpretation; wrote and edited the manuscript. All authors read  
952 and approved the final manuscript.

953 **Acknowledgements:** Not applicable.

Inclusion

Screening

Identification

Protein processing in endoplasmic reticulum

Autophagy - animal  
Ubiquitin mediated proteolysis

Shigellosis

Spinocerebellar ataxia


Proteoglycans in cancer

Cell cycle

p53 signaling pathway

Pathways in cancer

N-Glycan biosynthesis



■ # of miRNA Genes

■ # of Coding Genes

